Led by Senior, Bigfork Soccer Rising

first_img Stay Connected with the Daily Roundup. Sign up for our newsletter and get the best of the Beacon delivered every day to your inbox. BIGFORK – Now in its 10th year, the Bigfork High School girls soccer program has never had a winning record.And as the road to state may have gotten easier for other programs when the school dropped down from Class A to Class B, soccer stayed in the higher class. Class B doesn’t have soccer. So here are the Valkyries, coming off a 2009 season that started with high expectations but was thrown off course by a series of unfortunate injuries. The 2010 Valkyries believe this is their year. This could be the team that turns it all around. The Vals have five seniors. They have a roster of up-and-coming younger players. They have a first-year coach eager to rewrite the script for the program. And, as every other team in the state knows well, the Vals have Caitlin Charlebois.“She’s just a great player,” coach Charlie Appleby said. “She has a great sense for the ball. She knows how to put balls into other players. Her shot is great – she can score from anywhere, from 18 in, at any time. She’s always a threat.”But while Appelby, like others who have watched Charlebois, can pile on accolades, perhaps the most telling compliment – and probably the most important – is the praise over her unselfishness. If the Valkyries are going to earn a winning record and a trip to state, they must do it as a team. It starts with Charlebois, who Appleby calls “our captain and core of our offense,” and seeps through the rest of the roster.“That girl will do whatever it takes to help her team,” Appleby said. “She’s a team player and everybody on the team sees that and recognizes that. They like to get her goals.”He added: “She tries to bring everybody else in, which breaks her free.” Charlebois, an 18-year-old senior, is one of the top girls soccer players in Montana. As a sophomore, she scored 19 goals in 12 games. Last year, her goal total dipped, largely because she was focused more on distributing the ball to her teammates. Appleby points to that as evidence of her unselfishness. In both her sophomore and junior years, Charlebois was named Class A all-state. She’s fast and fluid on the field, with an innate ability to differentiate between when it’s appropriate to dictate the action and when it’s better to let the action come to her. Charlebois is a forward, but Appleby said he may drop her back to center-midfielder at times so she can run the offense as the core playmaker. She has played midfield in the past, for the same reason. Also a basketball and track standout, Charlebois’ athleticism allows her to seamlessly move to different positions.While Charlebois does say she would like to be named all-state again, that’s about as much as anybody can get her to talk about herself. When a question is directed at her in the form of “you,” she translates the answer into “we.”“If we play like we can, we’re in it with anybody this year,” Charlebois said. “I just want to help my team as much as possible.”In 2008, the Vals finished with four wins, seven losses and a tie, which Appleby said is the best record in the program’s history. Last year, the girls expected even a stronger season, but quickly lost two key players to season-ending leg injuries.Bigfork frequently had three or four players nursing injuries on the sidelines last year, which is hard on a program that barely gets enough girls to fill out the roster in the first place. This year, the team has 14 players. “I still feel like 14 is short-handed,” Appleby said. “But if we can stay healthy, 14 is great.” Despite injuries and the accompanying adversity, Appleby said his girls have maintained a “real positive attitude.” Appleby is in his first year as head coach, replacing Hauna Trennery. He was previously an assistant. “We haven’t had the best luck or the best teams over the past couple of seasons,” Appleby said. “But this team just seems tight and ready to win. They believe that they can.“They’re looking at each other and each other’s dedication and they leave it all on the field. And that’s what they’ve done for three years.” Quinci Paine, a senior, has watched the Vals gradually improve in her four years. During her freshman year, she said the team would regularly get blown out. The Vals lost 9-1 to perennial contender Columbia Falls, Paine recalls. Last year, the two teams tied. The Valkyries opened up this season by losing to Columbia Falls 5-1, but Paine said they’re still working out some kinks. The team is experimenting with two inexperienced goaltenders, who are improving daily but still finding their way. Paine plays both offense and defense, and was named all-conference last season. “I feel we played better than the score said,” Paine said of the opening-day loss. The Vals have to place in the top three out of five teams in Northern A to qualify for state. Last season, only the top two went. Northern A includes Libby, Whitefish, Columbia Falls and Polson. “We’ve never made it to state before, but this year we definitely have a chance,” Paine said.As the Valkyries try to navigate the Class A landscape to the state tournament in October, they will look to their compass, Charlebois. If her play can be inspiring, so too can her love of the game. “Since I’ve been little, I’ve loved pretty much everything about soccer,” Charlebois said. “I’ve never had a season that I regretted or didn’t absolutely love. Even the losing ones.” Emaillast_img read more

Accidental Discovery of New T-Cell Hailed as Major Breakthrough for ‘Universal’ Cancer Therapy

first_imgCardiff researchers have now discovered T-cells equipped with a new type of T-cell receptor (TCR) which recognizes and kills most human cancer types, while ignoring healthy cells.RELATED: FDA Approves Pancreatic Cancer Drug Treatment After It Was Shown to Double Patient LifespansThis TCR recognizes a molecule present on the surface of a wide range of cancer cells as well as in many of the body’s normal cells but, remarkably, is able to distinguish between healthy cells and cancerous ones, killing only the latter.The researchers said this meant it offered “exciting opportunities for pan-cancer, pan-population” immunotherapies not previously thought possible.Photo by Cardiff UniversityHow does this new TCR work?Conventional T-cells scan the surface of other cells to find anomalies and eliminate cancerous cells—which express abnormal proteins—but ignore cells that contain only “normal” proteins.The scanning system recognizes small parts of cellular proteins that are bound to cell-surface molecules called human leukocyte antigen (HLA), allowing killer T-cells to see what’s occurring inside cells by scanning their surface.MORE: Scientist Who Helped Develop Breakthrough Ovarian Cancer Treatment Donates All $1.2 Million in ProfitsHLA varies widely between individuals, which has previously prevented scientists from creating a single T-cell-based treatment that targets most cancers in all people.But the Cardiff study, published this week in Nature Immunology, describes a unique TCR that can recognize many types of cancer via a single HLA-like molecule called MR1.Unlike HLA, MR1 does not vary in the human population—meaning it is a hugely attractive new target for immunotherapies.Andrew Sewell and Garry Dolton / Cardiff UniversityWhat did the researchers show?T-cells equipped with the new TCR were shown, in the lab, to kill lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney and cervical cancer cells, while ignoring healthy cells.To test the therapeutic potential of these cells in vivo, the researchers injected T-cells able to recognize MR1 into mice bearing human cancer and with a human immune system.CHECK OUT: Husband-Wife Duo Has Developed ‘Gene and Cell Therapy’ Cancer Vaccine Now Being Tested on PatientsThis showed “encouraging” cancer-clearing results which the researchers said was comparable to the now NHS-approved CAR-T therapy in a similar animal model.The Cardiff group were further able to show that T-cells of melanoma patients modified to express this new TCR could destroy not only the patient’s own cancer cells, but also other patients’ cancer cells in the laboratory, regardless of the patient’s HLA type.Professor Andrew Sewell, lead author on the study and an expert in T-cells from Cardiff University’s School of Medicine, said it was “highly unusual” to find a TCR with such broad cancer specificity and this raised the prospect of “universal” cancer therapy.“We hope this new TCR may provide us with a different route to target and destroy a wide range of cancers in all individuals,” he said.RELATED: Apples, Tea, and Moderation—The 3 Ingredients for a Long Life“Current TCR-based therapies can only be used in a minority of patients with a minority of cancers.“Cancer-targeting via MR1-restricted T-cells is an exciting new frontier – it raises the prospect of a ‘one-size-fits-all’ cancer treatment; a single type of T-cell that could be capable of destroying many different types of cancers across the population.“Previously nobody believed this could be possible.”What happens next?Experiments are under way to determine the precise molecular mechanism by which the new TCR distinguishes between healthy cells and cancer.The researchers believe it may work by sensing changes in cellular metabolism which causes different metabolic intermediates to be presented at the cancer cell surface by MR1.MORE: Broccoli Isn’t Just Good For You—Scientists Find It Holds Molecule That Could Be the ‘Achilles’s Heel’ of CancerThe Cardiff group hope to trial this new approach in patients towards the end of this year following further safety testing.Professor Sewell said a vital aspect of this ongoing safety testing was to further ensure killer T-cells modified with the new TCR recognize cancer cells only.“There are plenty of hurdles to overcome however if this testing is successful, then I would hope this new treatment could be in use in patients in a few years’ time,” he said.Professor Oliver Ottmann, Cardiff University’s Head of Haematology, whose department delivers CAR-T therapy, said: “This new type of T-cell therapy has enormous potential to overcome current limitations of CAR-T, which has been struggling to identify suitable and safe targets for more than a few cancer types.”Professor Awen Gallimore, of the University’s division of infection and immunity and cancer immunology lead for the Wales Cancer Research Centre, said: “If this transformative new finding holds up, it will lay the foundation for a ‘universal’ T-cell medicine, mitigating against the tremendous costs associated with the identification, generation and manufacture of personalized T-cells.“This is truly exciting and potentially a great step forward for the accessibility of cancer immunotherapy.”Reprinted from Cardiff University(WATCH the explanatory video below)Be Sure And Share The Exciting News With Your Friends On Social Media…AddThis Sharing ButtonsShare to FacebookFacebookFacebookShare to TwitterTwitterTwitterShare to EmailEmailEmailShare to RedditRedditRedditShare to MoreAddThisMore AddThis Sharing ButtonsShare to FacebookFacebookFacebookShare to TwitterTwitterTwitterShare to EmailEmailEmailShare to RedditRedditRedditShare to MoreAddThisMoreResearchers at Cardiff University have discovered a new type of killer T-cell that offers hope of a “one-size-fits-all” cancer therapy.T-cell therapies for cancer—where immune cells are removed, modified and returned to the patient’s blood to seek and destroy cancer cells—are the latest paradigm in cancer treatments.The most widely-used therapy, known as CAR-T, is personalized to each patient, but it only targets a few types of cancers and has not been successful for solid tumors, which make up the vast majority of cancers.last_img read more

Genevieve ‘Vea’ Marie Woods Foreman

first_img As well as a host of nieces, nephews, great-nieces, great-nephews, extended family and friends.Genevieve is preceded in death by her parents Curley and Celestine Woods, her siblings Mitchell Leonard, Maudry Clark, Maude Jones, Yola Kibodeaux, Curley Woods, Jr., Bernadette Handy, Beulah Woods, Shirley Henry, and  her godchildren Patricia Landry, Quentin J. Beverly, and Steven Handy.Funeral service will be 11 a.m. Tuesday, June 30, 2020 at Gabriel Funeral Home Chapel with visitation from 9 a.m. until service time.Burial will follow in Live Oak Cemetery. To their union 2 children were born. Glenn Edward Foreman and Leanora Marie Foreman Jones (deceased).Genevieve leaves to cherish sweet and wonderful memories of her, her son Glenn (Jacquelyn) E. Foreman. Granddaughters Joi L. Foreman, Jennifer L. Foreman and Lindsey (Fabian) Jacko. Grandsons Tyrone Andrus, Sr. and Toryn (Kasandra) Foreman.Great-Grandchildren Tyrone Andrus, Jr., Tyron Andrus, Traven Andrus, Rashale Foreman, Toryn Foreman, Jr., Telisha Mott, Janisha Tatmon, Kimora Means, Kiah Means, Shane Foreman, Shederick Lyons, Shanice Lyons, Reagan Jacko, and Grayson Jacko.Godchildren Clifton ‘Cut’ Kibedeaux, Murray Henry, Curley John Beverly, Terry Woods Jacko,  Timothy ‘Clem’ Williams. She was employed by Continental Bag Company and Subsidiary of Langston Companies, Inc. in Crowley, Louisiana.After retiring she did Home Health. She enjoyed travelling, visiting with her friends and family as well as reading.Genevieve married and later divorced Lacy Jim Foreman (deceased).center_img Genevieve ‘Vea’ Marie Woods Foreman was born to the late Curley Woods and Celestine Lewis Woods on January 1, 1937 in Crowley, Louisiana.She belonged to Sacred Heart Catholic Church. God called His child home to rest on Sunday, June 21, 2020.She attended night school at Crowley High and graduated with her GED.last_img read more

Prosafe Secures Contract for Newbuild Accommodation Vessel (UK)

first_imgProsafe has been awarded a contract from Statoil (U.K.) Ltd for the provision of either the Safe Zephyrus or Safe Boreas accommodation support vessel at the Mariner project in the UK Continental Shelf of the North Sea.The contract has been awarded following a competitive tendering process and is for a firm period of 8 months with on-site operations planned to commence mid- April 2016. In addition, Prosafe has granted Statoil four additional one-month options linked to the Mariner project.Prosafe has also granted Statoil an 8-month option commencing mid-April 2017 with three additional one-month options linked to the Bressay project in the UK Continental Shelf of the North Sea. Statoil is required to exercise the 8-month option within March 2014, aligning with the project sanction.Lastly, and dependent on the Bressay project sanction, Prosafe has granted Statoil options through 2018 into 2019.Total value of the contract for the firm period award for the Mariner Project is approximately USD 76.3 million. The Safe Zephyrus or Safe Boreas provide Statoil with the flexibility of both DP3 and 12-point moored station keeping, together with the highest standard of accommodation facilities for the coming years.[mappress]Prosafe, June 11, 2013last_img read more